BRAF and colonic neoplasm: These results indicate that AUY922 and conceivably other HSP90 inhibitors are unlikely to achieve significant therapeutic responses in mutant BRAF colon cancers unless used in combination with inhibitors against MEK/ERK or/and PI3K/Akt.